<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952064</url>
  </required_header>
  <id_info>
    <org_study_id>Y（2021）052</org_study_id>
    <nct_id>NCT04952064</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke</brief_title>
  <official_title>Ganglioside GM1 in Acute Ischemic Stroke: a Prospective, Randomized, Blinded Assessment of Endpoints, and Multicenter Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of higher doses of&#xD;
      monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-2</measure>
    <time_frame>90 days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-1</measure>
    <time_frame>90 days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in National Institute of Health stroke scale</measure>
    <time_frame>7 days and 14 days</time_frame>
    <description>the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Barthel index (BI) scale</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>the minimum and maximum values of BI are 0 and 100, respectively; higher BI mean a good outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>changes in some serum biomarkers</measure>
    <time_frame>7 days and 14 days</time_frame>
    <description>serum biomarkers included SOD，BDNF，NGF，CRP，TNF-α，IL-6，IL-1β，VEGF，NO，MMP</description>
  </other_outcome>
  <other_outcome>
    <measure>The change of infarct volume</measure>
    <time_frame>3 days</time_frame>
    <description>The change of infarct volume showed by MRI compared with baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>200 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monosialoganglioside GM1, 200 mg/day, for 12-14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monosialoganglioside GM1, 400 mg/day, for 12-14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monosialoganglioside GM1</intervention_name>
    <description>Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days</description>
    <arm_group_label>200 mg group</arm_group_label>
    <arm_group_label>400 mg group</arm_group_label>
    <other_name>GM1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age: 18-80 years old；&#xD;
&#xD;
          -  2. Patients with anterior circulation cerebral infarction;&#xD;
&#xD;
          -  3. first stroke onset or past stroke without obvious neurological deficit (mRS&#xD;
             score≤1)；&#xD;
&#xD;
          -  4. Within 24 hours of onset；&#xD;
&#xD;
          -  5. 5 ≤NIHSS score ≤ 20；&#xD;
&#xD;
          -  6. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with hereditary abnormal glucose and lipid metabolism (gangliosidosis,&#xD;
             such as Tay-Sachs disease and retinal degeneration);&#xD;
&#xD;
          -  2. Hemorrhagic stroke;&#xD;
&#xD;
          -  3. Disturbance of consciousness (NIHSS1a≥1)，or cerebral arteritis, brain tumor, brain&#xD;
             trauma, intracranial infectious diseases;&#xD;
&#xD;
          -  4. Planed endovascular treatment;&#xD;
&#xD;
          -  5. Uncontrolled hypertension: systolic pressure ≥200 mmHg or diastolic pressure ≥110&#xD;
             mmHg;&#xD;
&#xD;
          -  6. Bleeding tendency (except for thrombolysis) or severe bleeding within 3 months;&#xD;
&#xD;
          -  7. Patients with malignant tumor or serious diseases;&#xD;
&#xD;
          -  8. Along with epilepsy, arthritis and other disease, which have effect on neurological&#xD;
             assessment;&#xD;
&#xD;
          -  9. History of autoimmune diseases, spinal trauma, various demyelinating diseases,&#xD;
             including acute inflammatory demyelinating polyneuropathy (Guillain Barre syndrome);&#xD;
&#xD;
          -  10. Unable or unwilling to cooperate due to mental diseases;&#xD;
&#xD;
          -  11. Abnormal liver and renal function: ALT, AST &gt; 2 times of the upper limit of normal&#xD;
             value, or Cr &gt; 1.5 times of the upper limit of normal value；&#xD;
&#xD;
          -  12. Hypersensitivity to monosialoganglioside and excipients of test drug;&#xD;
&#xD;
          -  13. History of drug abuse；&#xD;
&#xD;
          -  14. Pregnant or lactating women, pregnant plan or unwilling to use effective&#xD;
             contraception during the trial period;&#xD;
&#xD;
          -  15. Participating in other clinical trials within 3 months;&#xD;
&#xD;
          -  16. Other conditions which are unsuitable for this trial assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Huisheng, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Xinhong, Doctor</last_name>
    <phone>15309885658</phone>
    <email>450341972@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of ShenYang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Xinhong, Doctor</last_name>
      <phone>86-24-28897491</phone>
      <email>450341972@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>monosialoganglioside GM1</keyword>
  <keyword>Ischemic Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

